Evidence map›Paper›PMID 29343633›Full record

ReviewJournal of the Royal Society, Interface2018

Hydrogel biomaterials and their therapeutic potential for muscle injuries and muscular dystrophies.

Rachel Lev, Dror Seliktar

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of the Royal Society, Interface, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 96 citations in OpenAlex.

  1. Review
  2. Article
  3. Graphene and TiACS applied bio materials · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Potential Therapeutic Strategies for Skeletal Muscle Atrophy.Antioxidants (Basel, Switzerland) · 2022
    Review
  18. Review
  19. Review
  20. Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Rachel LevFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Technion City, Haifa 32000, Israel.
Dror SeliktarFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Technion City, Haifa 32000, Israel dror@bm.technion.ac.il.ORCID 0000-0001-6964-8567
Google (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Muscular diseases such as muscular dystrophies and muscle injuries constitute a large group of ailments that manifest as muscle weakness, atrophy or fibrosis. Although cell therapy is a promising treatment option, the delivery and retention of cells in the muscle is difficult and prevents sustained regeneration needed for adequate functional improvements. Various types of biomaterials with different physical and chemical properties have been developed to improve the delivery of cells and/or growth factors for treating muscle injuries. Hydrogels are a family of materials with distinct advantages for use as cell delivery systems in muscle injuries and ailments, including their mild processing conditions, their similarities to natural tissue extracellular matrix, and their ability to be delivered with less invasive approaches. Moreover, hydrogels can be made to completely degrade in the body, leaving behind their biological payload in a process that can enhance the therapeutic process. For these reasons, hydrogels have shown great potential as cell delivery matrices. This paper reviews a few of the hydrogel systems currently being applied together with cell therapy and/or growth factor delivery to promote the therapeutic repair of muscle injuries and muscle wasting diseases such as muscular dystrophies.

Indexed as

Muscular DystrophiesAnimalsBiocompatible MaterialsCell TransplantationHumansHydrogelsMuscle, SkeletalBiocompatible MaterialsHydrogelsbiomaterialsgrowth factorsmuscle cellsscaffoldstissue engineering

Identifiers

PMID29343633
PMCPMC5805959
OpenAlexW2784239442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.